The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2022 | Remaining questions for the treatment of patients with MSI/dMMR mCRC with immunotherapy
Romain Cohen, MD, PhD, Saint-Antoine Hospital, AP-HP, Paris, France, questions whether patients with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) require 1 or 2-years of treatment with the anti-PD-1, nivolumab, plus the anti-CTLA-4, ipilimumab. Dr. Cohen also questions whether we need to combine these immune checkpoint inhibitors for all patients due to the current FDA-approval of both nivolumab and ipilimumab as first-line monotherapy in this patient population and whether patients who progress on nivolumab monotherapy can be rescued with ipilimumab. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
